Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD-233A/B/C/D combination therapy in Type 2 Diabetes Mellitus
NCT07816198Phase 3Not yet recruiting
- Sponsor
- Addpharma, Inc.
- Start
- Sep 2026
- Primary completion
- Jun 2028
01
Overview
Phase 3, randomised, double-blind trial of AD-233A and AD-233B in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Addpharma, Inc. Primary endpoint: Hemoglobin A1c at 24 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
AD-233AAD-233B
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07816198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07816198.